H3K4(Me3) (1-20)

Product Name: H3K4(Me3) (1-20)

Purity: 95%

Molar Mass: 2226.6

Chemical Formula: C94H174N35O27

Storage: Store at -20??

Sequence: ARTKQTARKSTGGKAPRKQL

Application:

H3K4(Me3) (1-20) is a synthetic peptide corresponding to the first 20 amino acids of histone H3, trimethylated at the lysine 4 (K4) residue. This specific post-translational modification is a hallmark of actively transcribed gene promoters and is crucial for the regulation of gene expression. Trimethylation of H3K4 facilitates the recruitment of transcriptional activators and chromatin remodelers, thereby promoting an open chromatin state conducive to transcription. The H3K4(Me3) (1-20) peptide is extensively used in epigenetic research to study mechanisms of gene activation, chromatin structure, and the roles of histone modifications in development and disease. Its application is key to understanding transcriptional regulation and developing targeted epigenetic therapies.

Current Research:

H3K4 trimethylation is catalyzed by histone methyltransferases, such as SETD1 and components of the MLL complex. This modification is enriched at the transcription start sites of actively transcribed genes. It provides a binding platform for chromatin remodeling complexes and transcriptional coactivators, facilitating RNA polymerase II recruitment and transcription initiation. Applications in Research Transcriptional Regulation Studies H3K4(Me3) (1-20) is used to investigate the role of trimethylation in gene activation. It provides insights into the interaction of transcription factors and chromatin-binding proteins with active promoter regions. Enzyme Activity Assays This peptide serves as a substrate for studying histone methyltransferases (HMTs) and demethylases (HDMs) that specifically regulate H3K4 trimethylation. It aids in characterizing enzyme specificity, kinetics, and inhibition. Epigenetic Drug Development H3K4(Me3) (1-20) is employed in screening assays for small molecules targeting methyltransferases or demethylases involved in trimethylation dynamics. These studies support the development of epigenetic therapies for diseases such as cancer. Implications in Disease Dysregulation of H3K4 trimethylation is implicated in various pathologies, including cancer, metabolic disorders, and neurodevelopmental syndromes. Overactive methylation can lead to aberrant activation of oncogenes, while insufficient methylation may result in gene silencing or developmental defects. Understanding the dynamics of H3K4 trimethylation is critical for identifying therapeutic targets. Conclusion H3K4(Me3) (1-20) is a powerful tool for studying the epigenetic mechanisms underlying gene activation. Its utility in transcriptional regulation research, enzyme characterization, and drug discovery highlights its importance in advancing our understanding of chromatin biology and its role in health and disease.

Reference:

Li, H., Ilin, S., Wang, W., Duncan, E. M., Wysocka, J., Allis, C. D., & Patel, D. J. (2006). Molecular basis for site-specific read-out of histone H3K4me3 by the BPTF PHD finger of NURF. Nature, 442(7098), 91-95.